Dallas, TX Clinical Trials Report — May 2026

For Dallas residents considering participation in clinical research, May 2026 brings both urgent opportunities and exciting new avenues for contributing to medical science. Dallas currently hosts 1,441 recruiting clinical trials across 658 research facilities, making it a vibrant hub for medical innovation in Texas.

A significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals. A total of 79 clinical trials in Dallas are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Act Now: Trials Closing Soon

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions, from oncology to cardiovascular health, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (4 trials)
• Heart failure (3 trials)
• Breast cancer (3 trials)
• Renal cell carcinoma (2 trials)
• Gastroesophageal junction adenocarcinoma (2 trials)
• Brachycephaly (2 trials)
• Coronary artery disease (2 trials)
• Deformational plagiocephaly (2 trials)
• Deformational posterior plagiocephaly (2 trials)

For healthy individuals, 2 trials specifically seeking healthy volunteers are also closing soon, presenting a timely opportunity to participate in general health research.

Major New Research Opportunities in Dallas

This month, Dallas saw the opening of 31 new clinical trials, an increase from the 23 trials that launched in April 2026. This trend indicates a growing research landscape, with May's new trials surpassing the 27 new trials observed in March 2026.

May brings several high-profile new trials to Dallas, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This study is testing CagriSema for body weight loss in 2,500 participants living with obesity, with or without type 2 diabetes.
• The Canopy Cancer Collective, LLC is leading NCT07605702, "The Canopy Cancer Collective Clinical Registry Protocol," a large observational registry protocol aiming for 100,000 participants to systematically collect comprehensive data on gastrointestinal cancer patients.
• The University of Colorado, Denver is sponsoring NCT07569250, "Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization," an interventional study involving 7,220 participants. This study aims to create and test a text message program to encourage at-home colorectal cancer screening.
• The Duchenne Registry is behind NCT07609394, "Duchenne Electronic Health Record Study," an observational study with 2,500 participants. It aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy through electronic transfer.
• RAI Services Company is sponsoring NCT07598136, "A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers," involving 1,280 participants to assess abstinence from combustible cigarettes when provided with electronic nicotine delivery systems.

New trials this month are exploring a range of conditions, with the most frequent being obesity (3 trials), locally advanced (unresectable) or metastatic solid tumors (2 trials), subarachnoid hemorrhage, aneurysmal (2 trials), colorectal cancer (2 trials), mohs micrographic surgery (2 trials), and type 2 diabetes (2 trials). Drug trials account for the largest share of new studies, with 16 new drug trials, followed by 7 other types of studies and 4 biological trials.

Key sponsors for these new trials include Baylor Research Institute (5 trials) and University of Texas Southwestern Medical Center (5 trials), alongside industry leaders like Eli Lilly and Company (3 trials) and Novo Nordisk A/S (2 trials).

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 31 new trials launched this month, 7 are actively seeking healthy volunteers. Across Dallas, a total of 120 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Dallas's Leading Research Facilities

Dallas is home to some of Texas's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Texas Southwestern Medical Center (176 trials)
• UT Southwestern Medical Center (154 trials)
• UT Southwestern/Simmons Cancer Center-Dallas (90 trials)
• University of Texas Southwestern (56 trials)
• Research Site (41 trials)
• Baylor University Medical Center (35 trials)
• Parkland Memorial Hospital (34 trials)
• Mary Crowley Cancer Research (30 trials)
• Medical City Dallas Hospital (27 trials)
• UT Southwestern Simmons Cancer Center - RedBird (22 trials)
• The University of Texas Southwestern Medical Center (21 trials)
• Retina Foundation of the Southwest (21 trials)

These institutions, particularly the various UT Southwestern campuses and centers, offer a broad spectrum of research, from oncology at the Simmons Cancer Center to general medical advancements at Baylor University Medical Center and Parkland Memorial Hospital.

Broadening Your Search: Nearby Options in Texas

While Dallas offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include Houston (45 trials), San Antonio (20 trials), Austin (16 trials), Fort Worth (4 trials), El Paso (4 trials), McAllen (4 trials), Amarillo (3 trials), and Plano (3 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 31 new trials launched this month, 28 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, 1 is female-only, and 1 is male-only. Academic institutions continue to play a vital role in Dallas's research ecosystem, with the University of Texas Southwestern Medical Center (5 trials) and Baylor Research Institute (5 trials) sponsoring the most new studies. Industry sponsors like Eli Lilly and Company (3 trials) and Novo Nordisk A/S (2 trials) are also driving significant research efforts.

As we move further into spring, Dallas's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and explore new treatment options.